Zühlke Ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Limulalimula.chMay 2024 · $6.8M
Limula develops an automated, closed platform for manufacturing personalized cell and gene therapies, aiming to move production from open, manual methods to scalable automated processes.
BiotechDeep TechHardwareMedical DevicesLausanne, CH
Thomas Eaton(Founder & CEO)inYann Pierson(Founder & CTO)inCaroline Boudousquié(Head of Solutions)inOlivier Waridel(Head of Operations)in
Co-investorsLifeX VenturesVerve VenturesOxford Seed Fund
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.